Nucleus Global

nucleus-global.com

Nucleus Global is the largest privately held medical communications company in the world. Built on a reputation of scientific excellence and quality, we are a global leader in delivering world-class, innovative education and medical marketing services to the pharmaceutical and biotechnology industries.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

news image

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More

Research

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

news image

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More

Research

ORA, INC. LAUNCHES THE ORA EYECUPTM, A REVOLUTIONARY OPHTHALMIC RESEARCH TECHNOLOGY AT EYECELERATOR 2022

Ora, Inc. | September 29, 2022

news image

Ora, Inc., the world's leading ophthalmology clinical research firm, has formally launched a revolutionary mobile research platform, Ora EyeCupTM, which promises to transform patient data capture through high-resolution imaging, artificial intelligence (AI) analysis, and real-time patient feedback. The Ora EyeCupTM, a finalist in the Most Valuable Clinical Technology Award category at the Reuters Events Pharma Awards USA 2022, will be presented by Dr. Gustavo De Moraes, Chief Medical Officer...

Read More

PHARMACY MARKET, PHARMA TECH

FORCURA SIGNS CSI PHARMACY, MARKING ENTRY INTO HOME INFUSION MARKET

Businesswire | June 22, 2023

news image

Forcura, a healthcare workflow management company, announced that CSI Pharmacy, a nationally accredited specialty pharmacy that provides infusion therapy services, will adopt Forcura’s cloud-based technology to enhance patient onboarding, care plan management and care coordination. This agreement officially ushers Forcura into the home infusion market expanding their scope of practice to include another vertical of home-based care. Through Forcura, CSI Pharmacy will gradua...

Read More
news image

Business Insights

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More
news image

Research

ELI LILLY WINS FDA'S EMERGENCY NOD FOR COVID-19 ANTIBODY—BUT, THANKS TO MIXED DATA, IT'S LIMITED

Eli Lilly | November 11, 2020

The U.S. just had another COVID-19 drug authorized for emergency use. But the approval is limited—and, with at least one vaccine launch on the horizon, industry watchers wonder whether drugs to treat the illness have any staying power. The FDA authorized Eli Lilly’s bamlanivimab for emergency use on Monday, making it the first antibody therapy to win that distinction. Dubbed LY-CoV555, it's an anti-SARS-CoV-2 antibody therapy the Indianapolis pharma is co-developing with AbCeller...

Read More
news image

Research

ORA, INC. LAUNCHES THE ORA EYECUPTM, A REVOLUTIONARY OPHTHALMIC RESEARCH TECHNOLOGY AT EYECELERATOR 2022

Ora, Inc. | September 29, 2022

Ora, Inc., the world's leading ophthalmology clinical research firm, has formally launched a revolutionary mobile research platform, Ora EyeCupTM, which promises to transform patient data capture through high-resolution imaging, artificial intelligence (AI) analysis, and real-time patient feedback. The Ora EyeCupTM, a finalist in the Most Valuable Clinical Technology Award category at the Reuters Events Pharma Awards USA 2022, will be presented by Dr. Gustavo De Moraes, Chief Medical Officer...

Read More
news image

PHARMACY MARKET, PHARMA TECH

FORCURA SIGNS CSI PHARMACY, MARKING ENTRY INTO HOME INFUSION MARKET

Businesswire | June 22, 2023

Forcura, a healthcare workflow management company, announced that CSI Pharmacy, a nationally accredited specialty pharmacy that provides infusion therapy services, will adopt Forcura’s cloud-based technology to enhance patient onboarding, care plan management and care coordination. This agreement officially ushers Forcura into the home infusion market expanding their scope of practice to include another vertical of home-based care. Through Forcura, CSI Pharmacy will gradua...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us